Survival rates for most childhood cancers have improved over the last four decades. In the modern era of cancer treatment, more than 80% of those diagnosed with a pediatric malignancy will become 5-year survivors (1) . This progress has resulted in a growing population of adult survivors of childhood cancer, with current estimates that one in every 640 young adults aged between 20 and 39 years is a survivor of a pediatric malignancy (2) .
Survivors exposed to cranial radiotherapy (CRT) represent a subpopulation at particularly high-risk for long-term morbidity. It is established that within the first 5 to 10 years after CRT survivors of childhood acute lymphoblastic leukemia (ALL) are at increased risk for deficits in neurocognitive skills, including attention, working memory, and processing speed (3, 4) . Yet, it is unknown whether survivors, as they age, will demonstrate early onset of age-related memory problems or dementia. Thus, aging adult survivors of childhood ALL provide a "sentinel" population, representing the first large group of survivors exposed to CRT to reach the middle decades of life.
As survivors age, global brain injury from early CRT may reduce cognitive reserve, placing them at risk for early onset dementia or memory impairment (5, 6) . However, the prevalence of dementia and memory impairment in aging adult survivors of childhood ALL has not previously been established. Our objective was to estimate the prevalence of memory impairment; mild cognitive impairment (MCI), a state of cognitive function intermediate between the changes seen in aging and those fulfilling the criteria for dementia (7) ; and dementia in this population. We also wanted to determine whether neuroanatomical characteristics of dementia (eg, reduced hippocampal volume with increased activation and thinner parietal and frontal cortices) were associated with this memory impairment.
Statistical Analyses
Descriptive statistics for the entire eligible cohort and participants, stratified by CRT dose (24 Gy and 18 Gy) , and for the subset of survivors evaluated by MRI are provided in Table 1 . Age-adjusted z scores for the four composite memory domains and eight memory subtests were calculated based on comparison with normal data with ages grouped as specified in the scoring manual (10) . Impairment for each memory test was defined as a z score more than 1 standard deviation (SD) below the normal mean of zero (18) (19) (20) . Exact binomial tests were used to compare memory test impairment rates with 15% (1 SD) in the normal population, and Fisher exact tests were used to compare impairment rates between the two CRT dose groups. Multiple logistic regression models were developed to investigate the relationship between impairment and treatment factors (cumulative intrathecal and intravenous methotrexate and CRT doses). The models were adjusted for time from CRT, age at CRT, and sex. The small number of minority participants precluded analysis by race/ethnicity. Comparison of structural and functional neuroimaging measures between impaired and unimpaired survivors for both immediate and delayed memory function were assessed using two sample t tests. A P value of less than .05 was considered statistically significant, and all statistical tests were two-sided.
results

Survivor Characteristics
Of 443 eligible survivors, 265 (60%) completed the memory evaluation, of whom 85 also completed the MRI examination ( Table 1) . The median age at evaluation was 36 years (range = 25-54 years), and median time from CRT was 30 years (range = 15-46 years). CRT exposure was evenly distributed between high-(24 Gy, n = 138) and low-dose exposure (18 Gy, n = 127). Ninety-five percent of participants also received intrathecal methotrexate, whereas 75% received intravenous methotrexate exposure. There was no difference in the distribution of CRT dose (P = .12) or demographic characteristics between participants and nonparticipants. Because of the evolution of treatment strategies over the years, not surprisingly, patients treated with 24 Gy CRT were older with a longer time since CRT at evaluation and received lower doses of methotrexate than those treated with 18 Gy CRT (Table 1) .
Memory Impairment
Compared with age-adjusted normative rates, survivors who received 24 Gy CRT had increased impairment on domains assessing immediate memory (impairment rate = 33.8%, 95% confidence interval [CI] = 25.9% to 42.4%; P <.001) and delayed memory (impairment rate = 30.2%, 95% CI = 22.6% to 38.6%; P < .001) (Table 2), whereas no increase was seen after 18 Gy CRT. There was no evidence for increased impairment based on age at evaluation (Supplementary Table 2 , available online). On subtests evaluating logical memory (ie, narrative story recall) and design memory, higher CRT dose (24 vs 18 Gy) was associated with a higher prevalence of delayed memory impairment (logical: 28.3% vs 11.9%, P = .001; designs: 13.2% vs 3.2%, P = .003). However, no statistically significant CRT dose response was identified for immediate logical and design memory. The mean raw score for delayed logical memory among survivors who received 24 Gy CRT was equivalent to the mean score of adults older than 69 years in the general population (Table 3) . Similarly, 24 Gy CRT survivors at a mean current age of 41 years had performance that would be expected in the 55 to 64 year age range in the general population for verbal paired associations and visual reproduction. Survivors who received 24 Gy CRT also demonstrated accelerated aging on the design memory test (Figure 1) .
On multivariable analysis (Table 4) , 24 Gy CRT (vs 18 Gy CRT) was associated with a twofold increased risk for impaired immediate memory (odds ratio [OR] = 2.78, 95 % CI = 1.22 to 6.34) and delayed memory (OR = 2.21, 95% CI = 0.90 to 5.42), although the latter did not achieve statistical significance. Age at CRT, time from CRT, and cumulative intrathecal or intravenous methotrexate exposure were not statistically significantly associated with either immediate or delayed memory deficits. Among memory subtests, even after adjustment for other factors, 24 Gy CRT remained associated with increased impairment in delayed but not immediate design memory (Table 4) .
Reduced cognitive status, defined as low or very low on the BCSE, was identified after 24 Gy CRT (18.5%, 95% CI = 12.4% to 26.1%; P < .001), but not 18 Gy CRT (8.7%, 95% CI = 4.4% to 15.0%; P = .11), suggesting a CRT dose-response effect (Table 2 ). However, current employment rates were equivalent (63.8% in 24 Gy CRT and 63.0% in 18 Gy CRT) in both CRT dose groups, suggesting no difference in functional status. Multivariable analyses identified that both immediate memory (OR = 3.1, 95% CI = 1.3 to 7.5) and delayed memory impairment (OR = 4.3, 95% CI = 1.7 to 10.5), but not full-scale IQ, was associated with cognitive impairment.
Structural and Functional Neuroimaging
Impaired immediate memory was associated with smaller right (P = .02) and left (P = .008) temporal lobe white matter volumes on MRI structural imaging assessment ( Figure 2A ) and with increased radial diffusivity, an inverse measure of white matter integrity, in the right parietal (P = .04) and temporal lobes (P = .03) on diffusion tensor imaging ( Figure 2B ). Smaller right hippocampal volumes ( Figure 2C ) were associated with impaired immediate (P = .02) and delayed memory (P = .01). On functional MRI, activation (retrieval > encoding) in the left anterior hippocampus was associated with design memory impairment for all patients (P = .005) and within the 24 Gy (P = .04) ( Figure 2D ) but not 18 Gy population. Activation (encoding > retrieval) in the right posterior hippocampus was associated with visual reproduction impairment after 24 Gy CRT (P = .03) ( Figure 2D ). Impaired delayed memory was associated with thinner bilateral parietal and frontal cortices ( Figure 2 , E and F). * CRT = cranial radiotherapy; HD = high-dose; IT = intrathecal; IV = intravenous; MRI = magnetic resonance imaging; MTX = methotrexate; SD = standard deviation. † P values are two-sided and based on χ 2 test or two-sample t test for comparing the differences between the two radiation dose groups across demographic and treatment characteristics. ‡ Cumulative doses listed for IT MTX, IV MTX, and HD IV MTX calculated separately. 
Discussion
As with other neurocognitive abilities, memory functions tend to decline with older age. MCI typically represents a state in which memory has declined beyond what is believed to be acceptable for aging, and dementia refers to the state of decline in multiple cognitive domains of sufficient severity to affect function. Young children who sustain mild, focal brain injury have a high capacity for adaptation because of neuronal plasticity, although children with diffuse brain injury, exemplified by moderate to severe traumatic brain injury, are at increased risk for continued functional limitations and early onset of dementia (21, 22) . Like traumatic brain injury, survivors of childhood cancer treated with whole-brain CRT have sustained not focal but diffuse injury at a young age and may be at increased risk for early-onset memory loss and dementia. Specific aspects of delayed memory more commonly associated with aging and dementia have not been routinely assessed among survivors treated with CRT. Among studies that reported memory assessment in the first 5 to 10 years from CRT, evidence is equivocal regarding deficits in delayed memory (23) (24) (25) . However, we now identify that at a median age of 41 years, adult survivors of childhood cancer who received 24 Gy CRT have delayed recall of narrative events similar to the general population older than 69 years. Furthermore, these survivors function at a level one to two decades older than their chronologic age in their ability to recall verbal associations and to reproduce visual designs and patterns. These delayed memory findings suggest that survivors of childhood cancer who received 24 Gy CRT are experiencing early onset of cognitive aging.
Survivors who received 18 Gy CRT had no statistically significant impairment in immediate or delayed memory in the time interval studied. Those who received 24 Gy showed twice the rate of impairment relative to lower-dose CRT. Additionally, it appears that delayed memory may be more affected by CRT dose than immediate memory. Rates of impairment in delayed logical (narrative) and design memory are statistically significantly greater with increasing CRT dose, whereas impairments in immediate logical and design memory do not increase. Thus, an increase in CRT dose may selectively increase risk for delayed memory deficits compared with immediate recall, a pattern consistent with normal aging, but at a median age of 36 years. Thus, it is possible that CRT exposure to the developing central nervous system may result in reduced cognitive reserve that, over time, manifests as early onset of memory impairment. It will be important to continue to monitor memory performance in those who received 18 Gy CRT to determine whether decline becomes apparent over a longer postirradiation interval. Fortunately, the SJLIFE cohort provides a platform for longitudinal reassessment of this population across the lifespan.
In the general population, impairment in memory and reduced cognitive function may exist without evidence for frank dementia. In this study, impairment in cognitive status did not seem to manifest as a measurable change in functional status as employment rates did not differ between the two dose groups. This suggests that, rather than frank dementia, deficits in middle adulthood may be more consistent with MCI, a state of cognitive function intermediate between the changes seen in aging and those fulfilling the criteria for dementia (7) . Typically with MCI, patients and their families are aware of the increasing forgetfulness; however, functional activities are still intact. Longitudinal studies have shown that persons with MCI are at increased risk for the development of frank dementia (26) . Thus, continued longitudinal follow-up of this sentinel population is essential. Finally, multivariable models suggest this reduced cognitive function is not a product of established global cognitive injury (full-scale IQ) but rather is associated primarily with memory impairment. Survivors with memory and cognitive impairment demonstrated reduced integrity on structural and functional neuroimaging in anatomical regions established as essential for memory formation. The formation of new memories is mediated through the temporal lobes, including hippocampal and parahippocampal structures, whereas long-term recall requires additional processing in frontal and parietal lobes. Reduction in cortical volume and thickness, as well as white matter volume and integrity, among survivors with memory impairments lends supporting evidence for early onset of age-related changes or perhaps MCI. Although indices of radial diffusivity in the unimpaired survivors were approximately normal for age (27) , the survivors with impaired short-term memory demonstrated statistically significantly elevated diffusivity in the temporal-parietal memory network, which is consistent with patterns seen in patients with MCI (28) . Furthermore, these increased diffusivity measures are more indicative of an older population (29) . Similar to older subjects with cognitive impairment, these childhood cancer survivors with impaired delayed memory displayed atypical cortical thinning of the medial orbito-frontal and parietal regions (30) . Hippocampal volumes were approximately age appropriate on the left but displayed pronounced atrophy on the right, effectively eliminating the typical bilateral asymmetry (31) . Greater atrophy of the right hippocampus has been demonstrated in healthy older subjects that later develop profound neurocognitive impairments in memory (30, 32) . Functional MRI during the cued-recall memory task showed elevated hippocampal activation in patients with memory impairment. A similar pattern of compensatory hippocampal engagement during this task was reported for older adults with increased genetic risk for Alzheimer's disease, and altered hippocampal activation was predictive of subsequent progression to dementia (16) . Taken together, the structural and functional neuroimaging phenotype displayed by these survivors is most consistent with early aging and increased risk for memory impairment.
The strengths of this study include the large population of aging adult survivors with detailed ascertainment of their cancer therapy, the ability to compare populations based on CRT dose, the relatively long interval from CRT exposure, and use of a dedicated testing battery specifically validated and normalized for memory assessment in the general population. When interpreting the findings, study limitations should be also considered. We were not able on this cross-sectional evaluation to identify whether memory deficits increase with time from CRT. Such a relationship is essential to determine whether these memory findings are simply the result of the initial, static neurocognitive injury or, as hypothesized, are progressive with aging. Second, there is a risk of participation bias because survivors with perceived memory problems may be more likely to participate in the formal evaluation, which would result * For immediate, delayed, immediate design and delayed design memory, three patients were excluded from analysis because of missing data. CI = confidence interval; CRT = cranial radiotherapy; IT = intrathecal; IV = intravenous; OR = odds ratio. † P value is based on two-sided Wald's χ Figure 2 . Structural and functional neuroimaging measures were compared between impaired (black bars) and unimpaired (white bars) survivors for both immediate and delayed memory function using two sample, two-sided t tests. All survivors are included in analyses (A, B, C, E, and F), and only survivors that had received 24 Gy CRT are shown in (D). Statistically significant differences between groups were identified by a single asterisk (*) for P less than.05 and double asterisks (**) for P less than. in overestimation of rates. However, there were no obvious differences between participants and nonparticipants based on demographic or radiation-related factors. Third, it is important to note that in the evolution of ALL therapy, prophylactic CRT doses were reduced over time to limit neurocognitive injury; thus survivors who received 24 Gy CRT in an earlier treatment era also had an older chronologic age. However, the memory battery scores are age-adjusted to allow reasonable direct comparison for a doseresponse effect despite the age differential. In summary, we identified early onset of memory and cognitive impairment associated with CRT dose in survivors of childhood ALL still at a relatively young age. Structural and functional neuroimaging provides biologic plausibility that impairments are associated with neural pathways established as essential for memory formation. For certain delayed memory domains, survivors function at a cognitive age two and three decades beyond their chronological age. This evidence should result in revision of Long-term Follow-up Guidelines from the Children's Oncology Group to include evaluation of memory measures in aging adult survivors (33) . Although modern therapies for ALL have reduced or eliminated the use of CRT in front-line therapy, there are estimated to be more than 50 000 survivors of ALL in the United States, most of whom received CRT, who may benefit from early screening and diagnosis of MCI (2) . Additionally, although impairment in other cognitive domains after 18 Gy exposure has been established (34), in this cross-sectional assessment 18 Gy CRT resulted in minimal impairment in memory. Continued follow-up of this population is needed to determine their true risk for memory impairment as they age. Future studies should determine the longitudinal trajectory of memory loss and monitor for frank dementia as this population ages, and if longitudinal memory loss is confirmed, intervention strategies to slow that loss, such as physical activity interventions, should be considered. 
